{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:30:51Z","timestamp":1786347051340,"version":"build-2736575974"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The worldwide burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, powered by high prevalence of obesity and its associated metabolic insults. Though urgent, definitive treatment is not yet available. Empagliflozin, a sodium glucose co-transporter inhibitor has been suggested in both human and animal studies to have diverse beneficial effects in MASLD by anti-inflammation and anti-oxidative stress effects, but many of the underlying mechanisms remain unexplained. The main aim of this systematic review and meta-analysis was to evaluate the effects of empagliflozin\u2019s in preclinical animal studies trying to view new horizons for future treatment of MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>we searched the related animal preclinical studies in databases including Scopus, Web of Science, Cochrane library, Wily online library and PubMed. The research team screened the literature and extracted data; any discrepancies were resolved by the research team leader through discussion. The quality of research methods was assessed by SYRCLE (systematic review center for laboratory animal experimentation) risk of bias tool. The meta-analysis was guided by the Cochrane Handbook; statistical analyses were conducted via RevMan 5.4 offline version and Comprehensive Met analysis V3 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our meta-analysis included 17 studies, involving 584 animals. In comparison with the model group, empagliflozin significantly reduced steatosis markers including hepatic burden of lipids, including triglycerides and cholesterol, NAFLD Activity Score (NAS) and total serum cholesterol (TC). It also significantly reduced hepatic fibrosis markers including fibrosis grade, transforming growth factor-\u03b2 (TGF-\u03b2) and collagen type I alpha 1 chain) COL1A1). Beyond its anti-steatofibrotic effects, empagliflozin significantly downregulated hepatic expression of inflammatory and oxidative markers including tumor necrosis factor-alpha (TNF-\u03b1), interleukin-6 (IL-6) and malondialdehyde (MDA). Moreover, empagliflozin significantly improved glycemic indices including Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), serum insulin, and fasting blood sugar (FBS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Empagliflozin significantly protected the liver against steatosis and fibrosis by mitigating hepatic inflammation, oxidative stress and insulin resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1822157","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:34:15Z","timestamp":1784882055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies"],"prefix":"10.3389","volume":"17","author":[{"given":"Lashin S.","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Basic Dental Science, Faculty of Dentistry, Al-Ahliyya Amman University","place":["Amman, Jordan"]},{"name":"Department of Medical Physiology, Mansoura Faculty of Medicine","place":["Mansoura University, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed O.","family":"Mostafa","sequence":"additional","affiliation":[{"name":"Department of Basic Dental Science, Faculty of Dentistry, Al-Ahliyya Amman University","place":["Amman, Jordan"]},{"name":"Department of Oral Pathology, Faculty of Dentistry, Beni-Suef university","place":["Beni-Suef, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Alsharayiah","sequence":"additional","affiliation":[{"name":"Department of Basic Dental Science, Faculty of Dentistry, Al-Ahliyya Amman University","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Elkholy","sequence":"additional","affiliation":[{"name":"Department of Basic Dental Science, Faculty of Dentistry, Al-Ahliyya Amman University","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Basic Dental Science, Faculty of Dentistry, Al-Ahliyya Amman University","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"El-Mansy","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Medical Sciences, Faculty of Dentistry, Zarqa University","place":["Zarqa, Jordan"]},{"name":"Department of Medical Histology and Cell Biology, Faculty of Medicine, Mansoura University","place":["Mansoura, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd El Rahman M.","family":"Sharfeldeen","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Pathology, College of Dentistry, City University Ajman","place":["Ajman, UAE"]},{"name":"Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Assiut University","place":["Assiut, United Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gehan","family":"El Wakeel","sequence":"additional","affiliation":[{"name":"Department of Medical Physiology, Mansoura Faculty of Medicine","place":["Mansoura University, Egypt"]},{"name":"Department of Basic Dental Sciences, Faculty of Dentistry, The Hashemite University","place":["Zarqa, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelnaser A.","family":"Badawy","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Northern Border University","place":["Arar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Sulaiman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Northern Border University","place":["Arar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elryah I.","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University","place":["Arar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam Shabram","family":"Alenazi","sequence":"additional","affiliation":[{"name":"Department of Family & Community Medicine, Faculty of Medicine, Northern Border University","place":["Arar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed M.","family":"Alruwaili","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University","place":["Arar, Saudi Arabia"]},{"name":"Center for Health Research, Northern Border University","place":["Arar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Hamza","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU)","place":["Arar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamdouh","family":"Eldesoqui","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, College of Medicine, AlMaarefa University","place":["Dariyah, Saudi Arabia"]},{"name":"Research Center, Deanship of Scientific Research and Post-Graduate Studies, AlMaarefa University","place":["Dariyah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19046","DOI":"10.1038\/s41598-023-46288-5","article-title":"Empagliflozin suppresses hedgehog pathway, alleviates ER stress, and ameliorates hepatic fibrosis in rats","volume":"13","author":"Abdalla","year":"2023","journal-title":"Scientific Reports"},{"key":"B2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani","year":"2024","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12343","DOI":"10.3390\/cimb46110733","article-title":"Impact of Opuntia ficus-indica juice and empagliflozin on glycemic control in rats","volume":"46","author":"Alqudah","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid metabolism in MASLD and MASH: from mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Reports"},{"key":"B5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Therapy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31593","DOI":"10.1038\/s41598-025-17219-3","article-title":"Metabolic and hepatic biomarkers associated with MASLD in the Chinese population","volume":"15","author":"Chen","year":"2025","journal-title":"Scientific Reports"},{"key":"B7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12933-025-03042-7","article-title":"Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes","volume":"25","author":"Cliff","year":"2026","journal-title":"Cardiovascular Diabetology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1649630","DOI":"10.3389\/fphar.2025.1649630","article-title":"Novel insights into the hepatoprotective mechanisms of SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats","volume":"16","author":"Comella","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ueg2.70072","article-title":"The rising global burden of MASLD and other metabolic diseases (2000\u20132021)","volume":"13","author":"Danpanichkul","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/ijms26041778","article-title":"Current therapeutic landscape for metabolic dysfunction-associated steatohepatitis","volume":"26","author":"Devasia","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/hep.31886","article-title":"The glucagon-like Peptide-1 receptor agonist, semaglutide, for the treatment of nonalcoholic steatohepatitis","volume":"74","author":"Dichtel","year":"2021","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of inflammatory cytokines with non-alcoholic fatty liver disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.21037\/hbsn-2025-250","article-title":"Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition","volume":"14","author":"El-Kassas","year":"2025","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1007\/s00210-023-02826-6","article-title":"Empagliflozin ameliorates liver fibrosis in NASH rat model via targeting hepatic NF-\u03baB\/SOX9\/OPN signaling and osteocalcin level","volume":"397","author":"Elseweidy","year":"2024","journal-title":"Naunyn-schmiedeberg's Archives of Pharmacology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12902-025-02098-6","article-title":"Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial","volume":"25","author":"Erfanifar","year":"2025","journal-title":"BMC Endocrine Disorders"},{"key":"B16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/cimb47100846","article-title":"Empagliflozin Attenuates liver inflammation and Fibrosis in NAFLD: evidence from mendelian randomization and mouse experiments","volume":"47","author":"Fu","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.3390\/nu15133063","article-title":"The association between liver enzymes and mortality stratified by non-alcoholic fatty liver disease: an analysis of NHANES III","volume":"15","author":"Grob","year":"2023","journal-title":"Nutrients"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/biomedicines10051032","article-title":"Empagliflozin reduces the progression of hepatic fibrosis in a mouse model and inhibits the activation of hepatic stellate cells via the hippo signalling pathway","volume":"10","author":"Heo","year":"2022","journal-title":"Biomedicines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.3390\/ijms26094054","article-title":"Empagliflozin alleviates hepatic steatosis and oxidative stress via the NRF1 pathway in high-fat diet-induced mouse model of Metabolic dysfunction-associated steatotic liver disease","volume":"26","author":"Heo","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1539578","DOI":"10.3389\/fnut.2025.1539578","article-title":"Diet, oxidative stress and MAFLD: a mini review","volume":"12","author":"Hu","year":"2025","journal-title":"Front. Nutr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/dom.14670","article-title":"Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes","volume":"24","author":"Kahl","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"178209","DOI":"10.1016\/j.ejphar.2025.178209","article-title":"Bone marrow MSCs-derived exosomes (BM-MSCs-Exo) expressed mir-181, mir-24, mir-9, mir-29, mir-338, and mir-486 ameliorated hepatic fibrosis in male rats via altering the expression of Menin-1\/TGF-\u03b2\/Smad pathway","volume":"1007","author":"Khamis","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"114445","DOI":"10.1016\/j.biopha.2023.114445","article-title":"Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models","volume":"161","author":"Kim","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.jhepr.2025.101414","article-title":"Inflammation in MASLD progression and cancer","volume":"7","author":"Kim","year":"2025","journal-title":"JHEP Reports"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.3390\/ijms23105675","article-title":"Empagliflozin treatment attenuates hepatic steatosis by promoting white adipose expansion in Obese TallyHo mice","volume":"23","author":"Kurtz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2021.12.065","article-title":"Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease","volume":"588","author":"Lee","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fphar.2022.944886","article-title":"Empagliflozin activates Sestrin2-mediated AMPK\/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE (-\/-) mice by activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.2147\/dmso.s422327","article-title":"Metabolic and hepatic effects of empagliflozin on nonalcoholic fatty liver mice","volume":"16","author":"Niu","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.3390\/ijms22126332","article-title":"Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH","volume":"22","author":"Perakakis","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","volume":"498","author":"Petito-da-Silva","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s00125-022-05851-x","article-title":"Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis","volume":"66","author":"Radlinger","year":"2023","journal-title":"Diabetologia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.31989\/bchd.v8i3.1558","article-title":"Combination of empagliflozin and curcumin ameliorates the induced diabetic nephropathy in male albino rats, through their synergistic anti-diabetic and antioxidative effects","volume":"8","author":"Ramadan","year":"2025","journal-title":"Bioactive Compounds in Health and Disease-Online"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/hep.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12902-025-01882-8","article-title":"The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"25","author":"Shojaei","year":"2025","journal-title":"BMC Endocrine Disorders"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1111\/dom.15634","article-title":"Empagliflozin mitigates metabolic dysfunction\u2010associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes","volume":"26","author":"Smati","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1620585","DOI":"10.3389\/fimmu.2025.1620585","article-title":"Inflammation: a key mechanism connecting metabolic-associated steatotic liver disease and systemic arterial hypertension","volume":"16","author":"Solleiro-Villavicencio","year":"2025","journal-title":"Front. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e186420","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"The Journal of Clinical Investigation"},{"key":"B46","doi-asserted-by":"publisher","first-page":"268","DOI":"10.13181\/mji.oa.257855","article-title":"Empagliflozin for liver and lipid profile in metabolic dysfunction-associated fatty liver disease: a meta-analysis","volume":"34","author":"Suhardi","year":"2025","journal-title":"Med. J. Indones."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e105610","DOI":"10.1371\/journal.pone.0105610","article-title":"Carotid intima-media thickness is predicted by combined eotaxin levels and severity of hepatic steatosis at ultrasonography in obese patients with nonalcoholic fatty liver disease","volume":"9","author":"Tarantino","year":"2014","journal-title":"PLoS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/17474124.2021.1914587","article-title":"Liver-spleen axis in nonalcoholic fatty liver disease","volume":"15","author":"Tarantino","year":"2021","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1611400","DOI":"10.3389\/fphar.2025.1611400","article-title":"Natural active botanical metabolites: targeting AMPK signaling pathway to treat metabolic dysfunction-associated fatty liver disease","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in Diet-induced Obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"B51","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"9010","DOI":"10.3390\/ijms26189010","article-title":"The combination empagliflozin\/metformin attenuates the progression of metabolic dysfunction-associated steatotic liver disease in a diet-induced experimental rat model","volume":"26","author":"Zambrano-V\u00e1squez","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2022.941721","article-title":"Extrahepatic factors in hepatic immune regulation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1822157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:14:29Z","timestamp":1786346069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1822157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":53,"alternative-id":["10.3389\/fphar.2026.1822157"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1822157","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1822157"}}